The authors of this article are a group of experts in the field of gynecological pathology and oncology. They include W Glenn McCluggage, who is a professor and consultant pathologist at Queen's University Belfast and the Royal Group of Hospitals Trust in Northern Ireland; Meagan J Judge, who is a senior lecturer and consultant gynecological oncologist at University College London and University College London Hospitals NHS Foundation Trust in England; Blaise A Clarke, who is an associate professor and staff pathologist at the University of Toronto and the University Health Network in Canada; Ben Davidson, who is a professor and senior consultant pathologist at the University of Oslo and the Norwegian Radium Hospital in Norway; C Blake Gilks, who is a professor and division head of anatomic pathology at the University of British Columbia and Vancouver General Hospital in Canada; Harry Hollema, who is a professor and head of the department of pathology and medical biology at the University Medical Center Groningen in the Netherlands; Jonathan A Ledermann, who is a professor and director of the Cancer Research UK and UCL Cancer Trials Centre at University College London and honorary consultant medical oncologist at University College London Hospitals NHS Foundation Trust in England; Xavier Matias-Guiu, who is a professor and head of the department of pathology and molecular genetics at the Hospital Universitari Arnau de Vilanova and the Biomedical Research Institute of Lleida in Spain; Yoshiki Mikami, who is a professor and chair of the department of diagnostic pathology at Kyoto Prefectural University of Medicine in Japan; Colin J R Stewart, who is a professor and consultant pathologist at the National University of Singapore and National University Hospital in Singapore; Russell Vang, who is an associate professor and director of gynecologic pathology at Johns Hopkins University School of Medicine and Johns Hopkins Hospital in the USA; and Lynn Hirschowitz, who is a reader and honorary consultant gynecological pathologist at the University of Birmingham and Birmingham Women's NHS Foundation Trust in England.
This article presents the International Collaboration on Cancer Reporting (ICCR) dataset for the reporting of ovarian carcinoma. The ICCR is a not-for-profit organization that aims to develop standardized, evidence-based and internationally agreed-upon datasets for the pathology reporting of cancer. The ICCR datasets are intended to promote consistent and accurate reporting of cancer, facilitate research and audit, and improve patient care and outcomes.
The ICCR dataset for ovarian carcinoma was developed by a panel of 12 experts from 8 countries, representing different regions and practice settings. The panel reviewed the existing literature and guidelines on ovarian carcinoma pathology reporting, and consulted with various stakeholders, including pathologists, oncologists, surgeons, radiologists, patients and advocacy groups. The panel also considered the feedback from an open consultation process that involved more than 200 pathologists from 31 countries.
The ICCR dataset for ovarian carcinoma consists of 38 core (mandatory) and 13 non-core (optional) data elements that cover the essential information for the diagnosis, classification, staging and prognostication of ovarian carcinoma. The dataset also provides guidance on specimen handling, macroscopic and microscopic examination, immunohistochemistry and molecular testing, and report format and terminology. The dataset is applicable to all types of ovarian carcinoma, including epithelial, germ cell, sex cord-stromal and metastatic tumors. e0e6b7cb5c